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There is limited information on antivenom pharmacokinetics. This study aimed to investi-
gate the pharmacokinetics of an Indian snake antivenom in humans with Russell’s viper
bites.
Methods/Principal Findings
Patient data and serial blood samples were collected from patients with Russell’s viper
(Daboia russelii) envenoming in Sri Lanka. All patients received Indian F(ab’)2 snake anti-
venom manufactured by VINS Bioproducts Ltd. Antivenom concentrations were measured
with sandwich enzyme immunoassays. Timed antivenom concentrations were analysed
using MONOLIXvs4.2. One, two and three compartment models with zero order input and
first order elimination kinetics were assessed. Models were parameterized with clearance
(CL), intercompartmental clearance(Q), central compartment volume(V) and peripheral
compartment volume(VP). Between-subject-variability (BSV) on relative bioavailability (F)
was included to account for dose variations. Covariates effects (age, sex, weight, anti-
venom batch, pre-antivenom concentrations) were explored by visual inspection and in
model building. There were 75 patients, median age 57 years (40-70y) and 64 (85%) were
male. 411 antivenom concentration data points were analysed. A two compartment model
with zero order input, linear elimination kinetics and a combined error model best described
the data. Inclusion of BSV on F and weight as a covariate on V improved the model. Inclu-
sion of pre-antivenom concentrations or different batches on BSV of F did not. Final model
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003873 July 2, 2015 1 / 13
a11111
OPEN ACCESS
Citation: Isbister GK, Maduwage K, Saiao A,
Buckley NA, Jayamanne SF, Seyed S, et al. (2015)
Population Pharmacokinetics of an Indian F(ab')2
Snake Antivenom in Patients with Russell's Viper
(Daboia russelii) Bites. PLoS Negl Trop Dis 9(7):
e0003873. doi:10.1371/journal.pntd.0003873
Editor: José María Gutiérrez, Universidad de Costa
Rica, COSTA RICA
Received: April 4, 2015
Accepted: June 2, 2015
Published: July 2, 2015
Copyright: © 2015 Isbister et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Data are available on
NOVA, the University of Newcastle's institutional
digital repository at the URL http://hdl.handle.net/
1959.13/1063469
Funding: The study was supported in part by
NHMRC Project Grant 631073. GKI is funded by an
NHMRC Senior Research Fellowship ID1061041.
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
parameter estimates were CL,0.078 Lh-1, V,2.2L, Q,0.178Lh-1 and VP,8.33L. The median
half-life of distribution was 4.6h (10-90%iles:2.6-7.1h) and half-life of elimination, 140h
(10th-90th percentilesx:95-223h).
Conclusion
Indian F(ab’)2 snake antivenom displayed biexponential disposition pharmacokinetics, with
a rapid distribution half-life and more prolonged elimination half-life.
Author Summary
Snake envenoming is a neglected tropical disease that affects hundreds of thousands of
people in the rural tropics. Antivenom is the main treatment for snake bites but there is
limited information on the pharmacokinetics and appropriate dosing regimen. Most stud-
ies have been done in animals and dosing guidelines are based on arbitrary and often irre-
versible clinical signs. In this study we measured serial antivenom concentrations in
patients with Russell’s viper envenoming given antivenom. Using this data we modelled
the pharmacokinetics of antivenom in the population and showed that antivenom concen-
trations had a bi-exponential decay with an initial decrease over 12 hours and then a slow
decrease over days. There was significant variability in the dose given which was not
affected by the particular antivenom batch given. The presence of venom did not appear to
modify the pharmacokinetics of antivenom. Understanding the time course of antivenom
in patients with snake envenoming will provide a better basis for antivenom dosing.
Introduction
Snake envenoming is a major health issue in South and South-eastern Asia [1]. Although anti-
venom is the most important treatment for snake envenoming, it can cause early systemic
hypersensitivity reactions [2, 3], and there is limited evidence to support currently practiced
dosing schedules. Dosing and assessment of the effectiveness of antivenom in human enven-
oming remains controversial and treatment protocols are not based on the kinetics of venom
or antivenom. There are few studies of the pharmacokinetics of antivenom, and most of these
are in animals [4].
Snake envenoming is a common problem in Sri Lanka and large amounts of antivenom are
used throughout the country each year. A number of different Indian antivenoms are currently
used and the initial dose ranges from 10 to 20 vials [5–7]. The initial dose is based on ED50
studies and clinical experience by titrating dose against the resolution of coagulopathy and
neurotoxicity. However, the clinical effects of envenoming in these species are generally irre-
versible so determining if enough antivenom has been given and deciding to re-dose is often
arbitrary and not based on whether all venom has been bound, or on the pharmacokinetics of
antivenom. Measurement of venom and antivenom concentrations in patients with snake bite
is required to improve effective initial and repeat dosing [8].
The pharmacokinetics of antivenom are expected to be similar to other intravenous drugs
being delivered to the central compartment with zero order input kinetics (constant rate of
infusion). Antivenom is then distributed throughout the body and is eliminated by the kidneys
and/or the reticuloendothelial system [4]. Decreasing antivenom concentrations in the central
compartment are therefore due to both distribution and elimination. Different types of
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antivenom have different pharmacokinetics due to the difference in their molecular masses [4].
Fab antivenoms have much larger volumes of distribution (VD) than F(ab’)2 or whole IgG [5,
9]. Most studies of antivenom pharmacokinetics show a biphasic (two-compartment) decline
after intravenous administration of whole IgG and F(ab’)2 antivenoms, as a result of an initial
rapid decline (distribution phase) and a slower decline (terminal elimination phase) [4, 9].
Most studies of the pharmacokinetics of antivenom are in animals [4, 10], and the pharma-
cokinetics appear to differ between animals making animal models problematic for defining
the pharmacokinetics of antivenom in humans [10]. Although there have been several publica-
tions of antivenom concentrations in snake envenoming, there are only a few studies of the
pharmacokinetics of antivenom in human snake envenoming [4, 5, 9, 11–14]. These studies
were all in small numbers of patients using a classic two phase approach, without including
input processes (i.e. delivery of the antivenom, usually via an infusion to the central compart-
ment as a zero order process) and providing limited information on the pharmacokinetics and
variation between patients.
A population approach to pharmacokinetic analysis is increasingly being used to define the
pharmacokinetics of drugs in humans because it provides information about population vari-
ability and the need for individualisation of drug treatment. The traditional approach to phar-
macokinetic analysis (two stage analysis) estimates the pharmacokinetic parameters for each
individual patient and then provides summary statistics which only give a population average
and standard error. In contrast the population approach estimates the typical value of each
parameter for the population and the variability of the parameters simultaneously. This pro-
vides an estimate of unexplained random variation and allows the effects of covariates to be
accounted for in the model (e.g. weight, renal function). There are no previously published
population pharmacokinetic analyses of antivenom in humans or animals.
The aim of this study was to investigate the pharmacokinetics of antivenom in patients with
snake bites using a population based analysis, including an investigation of the covariates that
may influence the pharmacokinetics of antivenom.
Methods
This was a population pharmacokinetic analysis of an F(ab’)2 antivenom using data and serial
antivenom concentrations collected in snake-bite patients admitted to a single hospital in Sri
Lanka. The patients were recruited from within a large cohort of snakebites admitted to the
Base Hospital Polonnaruwa in Central Eastern Sri Lanka.
Ethics statement
The study was approved by the Ethical Review Committee, Faculty of Medicine, University of
Peradeniya, Sri Lanka. All patients gave written and informed consent for the collection of clin-
ical data and blood samples.
Patients
All patients (>15 years old) from October 2010 to March 2012 with a suspected snake bite who
presented to the Base Hospital Polonnaruwa were recruited to a prospective cohort study.
Those with coagulopathy were then entered in a dose finding randomised clinical trial of fresh
frozen plasma. The entry criteria for the trial was a suspected Russell’s viper (Daboia russelii)
bite with coagulopathy defined as an abnormal 20 minute whole blood clotting test
(20WBCT). This resulted in a small number of patients being recruited where Russell’s viper
(D. russelii) venom was not detected and on further testing, hump-nosed viper (Hypnale spp.)
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venom was detected (in some Hypnale bites the 20WBCT and coagulation studies may be
abnormal [15, 16]).
In this pharmacokinetic study, patients were only recruited from the clinical trial and were
included if they had serial serum collection for antivenom measurement and complete demo-
graphic details (including weight). All patients received the Indian polyvalent snake antivenom
intravenously manufactured by VINS Bioproducts Limited (batch numbers: 1060 [MFD 2008],
1096 [MFD 2009], 1102 [MFD 2009], 01015/10-11 [MFD 2010], 01AS11112 [MFD 2011]). For
a dose of antivenom, each of 10 vials of antivenom are reconstituted in 10ml of normal saline
for a total of 100ml of antivenom. From a 500ml bag of normal saline 100ml volume is
removed and replaced by the 100ml of antivenom so the 10 vials are administered in a total of
500ml of normal saline. This is given over 1 hour.
Data collection
The following data were collected prospectively in all cases: demographics (age, sex and
weight), time of the snake bite, clinical effects (local envenoming, coagulopathy, bleeding and
neurotoxicity) and antivenom treatment (dose, time of administration and antivenom batch
number). Blood samples were collected for research on admission and regularly throughout
each patient admission. Blood was collected in serum tubes for venom-specific enzyme immu-
noassay (EIA) and antivenom EIA. All blood samples were immediately centrifuged, and then
the serum aliquoted and frozen initially at -20°C, and then transferred to -80°C within 2 weeks
of collection.
Enzyme immunoassays for venom and antivenom
A sandwich enzyme immunoassay was used to measure antivenom in serum samples as previ-
ously described [8, 17]. The plate was first coated with Russell’s viper venom and then stored
and blocked overnight. Serum was then added to the plates. The detecting antibodies were con-
jugated with horseradish peroxidase. Russell’s viper (D. russelii) and hump-nosed (Hypnale
spp.) viper venoms were measured in samples with a venom specific enzyme immunoassay as
previously described [6, 8, 17]. Briefly, polyclonal IgG antibodies were raised in rabbits against
Russell’s viper (D. russelii) and hump-nosed viper (Hypnale spp.) venom. The antibodies were
then bound to microplates and also conjugated to biotin for a sandwich enzyme immunoassay
using streptavidin-horseradish peroxidase as the detecting agent. All samples were measured in
triplicate, and the averaged absorbance converted to a concentration using a standard curve
made up with serial dilutions of antivenom and using a sigmoidal curve. The limit of quantifi-
cation for the antivenom enzyme immunoassay assay was 40μg/ml and for the venom enzyme
immunoassay was 2ng/mL for Russell’s viper and 0.2ng/ml for hump-nosed viper.
Pharmacokinetic analysis
Patient data was analysed using MONOLIX version 4.2 (Lixoft,Orsay, France. www.lixoft.
com). MONOLIX uses the Stochastic Approximation Expectation Maximization algorithm
(SAEM) and a Markov chain Monte-Carlo (MCMC) procedure for computing the maximum
likelihood estimates of the population means and between-subject variances for all parameters
[18]. One, two and three compartment models with zero order input and first order elimina-
tion kinetics were assessed and compared to determine the best structural model. Proportional
and combined models were evaluated for the residual unexplained variability. Method M3 was
used to deal with antivenom concentrations below the limit of quantification (BLQ) [19].
Between-subject variability (BSV) was included in the model and assumed to have log-normal
distribution.
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Models were parameterized in terms of volume of distribution (VD; V, VP, VP2), clearance
(CL), inter-compartmental clearance (Q; Q1, Q2) and relative bioavailability (F) for either 1-,
2- or 3-compartment models. Initial estimates of parameters were taken from a previous phar-
macokinetic study of anti-venom [9].
Uncertainty in antivenom dose was included in the model by allowing BSV on F to account
for batch to batch variation in antivenom (five different batches) and for variation within
batches. F was fixed to 1 and the BSV was estimated for each patient similar to including uncer-
tainty on dose as previously described [18]. The BSV on F was plotted for each batch to deter-
mine if there was a difference between batches.
The effect of covariates, including age, sex, weight, and pre-antivenom concentrations in
patients with detectable venom, were explored by visual inspection of the individual parameter
estimates versus the covariate of interest. Age, sex and pre-antivenom concentrations were not
included in the final model evaluation due to the absence of an association visually. The influ-
ence of weight (wt) on volume was included in the modelling process. Weight was assumed to
be related to V by a power function. The covariate was centred to the average weight. Thus in
the model the estimation of the effect of weight on volume is:
V ¼ yV x ðwt=wtavÞ ^ f wt
Where θV is the typical value of volume of distribution, wt is the individual patient weight, wtav
is the average weight and fwt accounts for the inﬂuence of wt on volume.
Model selection decisions were based on a decrease in the objective function (OFV), a
decrease in residual error, clinical relevance of the pharmacokinetic parameters and goodness
of fit plots. The log likelihood was computed for each model and used to discriminate through
the difference in log likelihood (−2LL). A p-value of 0.05 was considered statistically signifi-
cant, equivalent to a drop in OFV by 3.84.
Simulations
From the final model we simulated 1000 patients using the individual predicted patient param-
eters from the final model with MatLab to explore different initial doses and repeat doses. The
following scenarios were explored:
1. One dose (10 vials) of antivenom given with infusions rates of 20 minutes, 1 hour and 2
hours.
2. Two doses of antivenom given, each over 1 hour and 6 hours apart.
3. Two doses of antivenom given, each over 1 hour and 12 hours apart.
The median antivenom concentration versus time was plotted with 10% and 90% percentiles.
Results
Patients
There were 75 patients with a median age of 38 years (16 to 64y) and 64 were male. Seventy one
were Russell’s viper envenoming cases and 52 of these had detectable venom prior to the admin-
istration of antivenom. Four patients had hump-nosed viper envenoming (confirmed by detect-
able hump-nosed viper venom). In all four patients with hump-nosed viper envenoming there
was a steady decline of venom concentrations despite the administration of antivenom consis-
tent with the antivenom not being raised against this snake venom. In nineteen patients meeting
the inclusion criteria venom was not detected prior to antivenom, most likely because the blood
was collected prior to envenoming. The demographics of the patients are listed in Table 1.
Pharmacokinetics of Indian Snake Antivenom
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There were 510 antivenom concentration data points but only 411 had detectable anti-
venom, the other 99 were serial samples after the disappearance of antivenom. There were 54
patients who had a single dose of antivenom who had 265 antivenom concentration measure-
ments with a median of five antivenom concentrations in each patient (Range: 2 to 10), and a
median antivenom concentration of 1607μg/ml (Range: 40 to 13673μg/ml). There were 21
patients who had multiple doses of antivenom who had 146 antivenom concentrations with a
median of seven antivenom concentrations in each patient (Range: 3 to 11) and a median anti-
venom concentration of 2293μg/ml (Range: 40 to 12599μg/ml). The observed concentration
versus time data is shown in Fig 1.
Pharmacokinetic analysis
A two compartment model with zero order absorption and linear elimination kinetics and a
combined error model best described the data. The final model incorporated BSV on F, which
was fixed to 1 to allow variability between patients in dose. The model also incorporated weight
as a covariate with a power effect on central volume, V. The inclusion of pre-antivenom con-
centrations on BSV of F did not improve the model. Plots of the BSV on F versus the batch
number showed no relationship between the batch and BSV on F (S1 Fig). The final model
Table 1. Demographics and clinical information of 75 patients who were administered Indian anti-
venom, including clinical features of envenoming, treatment and outcomes.
Median (range) Number (%)
Age (years) 38 (16 to 64) 75 (100)
Male - 64 (85)
Weight (kg) 57 (40 to 70)
Clinical Effects
Local envenoming 73 (97)
Coagulopathy (20WBCT+) 75 (100)
Systemic Bleeding 26 (35)
Neurotoxicity (ptosis) 32 (43)
Antivenom batch
1060 (MFD 2008) 1 (1)
1096 (MFD 2009) 8 (11)
1102 (MFD 2009) 12 (16)
01015/10-11 (MFD 2010) 40 (53)
01AS11112 (MFD 2011) 14 (19)
Antivenom dose (vials) 18 (8 to 40)
Repeat antivenom dose 21 (28)
Median pre antivenom venom concentration ng/ml (range) 169 (2 to 2805)† 52 (69)
Fresh Frozen Plasma (FFP)
2 Units FFP 44 (59)
4 Units FFP 14 (19)
8 Units FFP 1 (1)
Length of hospital stay (days) 2 (1 to 10)
Antivenom concentrations (μg/ml) 1916 (27 to 13673) 392 samples*
* Samples with antivenom measured in them from a total of 510 samples, 128 had no detectable
antivenom;
† Russell’s viper venom only detectable in 53 patients; 20WBCT– 20 minute whole blood clotting test.
doi:10.1371/journal.pntd.0003873.t001
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parameter estimates were CL, 0.078 Lh-1, V, 2.2L, Q, 0.178Lh-1 and VP, 8.33L. The median
half-life of distribution was 4.6h (10th-90th percentiles: 2.6 to 7.1h) and the half-life of elimina-
tion, 140h (10th-90th percentiles: 95 to 223h). There was no difference in the parameter esti-
mates between those with Russell’s viper envenoming with detectable venom prior to
antivenom (52), those with Russell’s viper envenoming and no detectable venom prior to anti-
venom (19) and those with hump-nosed viper envenoming (S2 Fig). S3 and S4 Figs shows the
goodness-of-fit plots for the final model. The individual PK parameter estimates from the base
models with modelling decisions and final model parameters are described in Table 2. There
Fig 1. Plots of the observed antivenom concentration (μg/ml) versus time for patients given a single dose of antivenom (A), and for patients given
multiple antivenom doses (B).
doi:10.1371/journal.pntd.0003873.g001
Table 2. Parameter estimates using Monolix version 4.2.
Base model Model 1 Model 2 Model 3 (Final)
Mean value (rse%) Including F Including weight on V Including F and weight on V
Structural model (θ)
CL (Lh-1) 0.0445 (50) 0.038 (65) 0.129 (23) 0.0779 (34)
V (L) 2.23 (9) 1.98 (11) 2.12 (11) 2.16 (10)
Q (Lh-1) 0.171 (21) 0.271 (20) 0.107 (38) 0.178 (31)
Vp (L) 17.6 (50) 14.1 (43) 3.27 (121) 8.33 (52)
fwt - - 0.137 (96) 0.132 (84)
F - 1 (-) - 1 (-)
Between subject variance (ω)
Cl 1.64 (47) 0.451 (81) 0.886 (30) 0.715 (46)
V 0.42 (22) 0.0627 (74) 0.419 (30) 0.188 (126)
Q 0.738 (33) 0.237 (71) 2.57 (84) 0.533 (57)
Vp 1.24 (57) 1.62 (56) 0.782 (282) 0.836 (125)
F - 0.309 (23) - 0.197 (42)
Objective Function (-2 log-likelihood value) 6840.81 6823.54 6835.96 6820.75
CL = clearance, V = volume of the central compartment, Q = intercompartmental clearance, Vp = volume of the peripheral compartment, fwt = effect of
weight on V, F = relative bioavailability.
doi:10.1371/journal.pntd.0003873.t002
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was also no difference in parameter estimates between patients given 1 dose of antivenom and
those given 2 doses, or between patients with different initial venom concentrations (S5 Fig).
Simulations for one dose (10 vials) of antivenom given over 20 minutes, 1 hour and 2 hours
shows there is a slightly lower and later peak antivenom concentration with slower infusions
(Fig 2). Simulations for two doses of antivenom shows that antivenom concentrations decrease
rapidly after each dose and there are low but persistent levels of antivenom after one dose and
both two doses regimens (Fig 3).
Discussion
The study adds to the limited information available on the pharmacokinetics of antivenom in
humans supporting previous studies [4, 9]. Indian F(ab’)2 snake antivenom displayed biexpo-
nential disposition pharmacokinetics, with a rapid half-life of distribution and a much longer
half-life of elimination. Weight accounted for some of the variability in the central volume, and
the volumes of the central and peripheral compartment were consistent with a large molecule
which does not have a large volume of distribution. Including variability on F improved the
model showing that there was significant random variability in dose. The plots in Figs 2 and 3
show the expected antivenom concentration profiles in the first 24 hours after administration.
Previous human and most animal studies have also shown a biexponential decay in anti-
venom concentrations [4, 9, 20, 21], with similar values for the distribution half-life of 2 to 4
hours and much longer elimination half-life of 90 to 230h. Previous studies have been small
with 10 or less patients in each analysis (for different antivenoms) and a classic two phase
approach has been undertaken. Such an approach will over-estimate the error and not account
for true random variability or covariate effects. In this study we have undertaken a population
approach, which provides information on the variability of the pharmacokinetics in the popu-
lation and an improved model by including weight and variability in dose. Previous studies
have not shown why they chose particular models (2-compartment versus 3-compartment),
with no statistical criteria or goodness of fit plots.
Some previous animal models and one human study have described the pharmacokinetics
with a tri-exponential decay in animals [14, 22, 23]. These analyses have not included an input
process in the analysis which will bias the estimation of the disposition parameters, particularly
with three or more compartments when the initial very short half-life is similar to the time of
the input phase. Ismail et al. estimated the initial rapid half-life in animals to be 0.2h and Vaz-
quez et al estimated it to be 0.25h, which are both similar to the usual infusion rate of anti-
venom over 10 to 30 minutes. It is possible that there is only 2-compartmental disposition
kinetics in these studies, and future pharmacokinetic analyses need to include an input phase
in the model. A possible limitation of our study was that there may have been insufficient sam-
pling in the initial period after antivenom administration to detect a third compartment. In
contrast to this, Vazquez et al were likely to have taken samples in the input phase, since the
first sample was taken 5min after antivenom administration, although they do not report the
infusion time or rate [14].
One animal study of a F(ab’)2 has shown that the pharmacokinetics of antivenom are the
same in envenomed and non-envenomed rabbits [24]. This is consistent with this study dem-
onstrating that pre-antivenom venom concentrations did not influence the pharmacokinetics
of antivenom, including different initial venom concentrations (S5 Fig). However, this may
be different for Fab antivenoms where high molecular weight toxins may change the route of
elimination from renal (for free Fab antivenom) to phagocytosis/reticulo-endothelial system
for Fab-toxin molecules. The latter has been shown in rabbits with anti-Vipera Fab anti-
venom [25].
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There has always been concerns about the variability between different batches of anti-
venom leading to potential differences in the dose administered between batches. The study
did not support this concern and found that there was no difference in F on average between
different batches (S1 Fig). However, the study found that including between subject variability
on relative bioavailability did improve the model. This suggests there was random variability in
the dose administered which is likely to be due to variable losses occurring during reconstitu-
tion of the individual freeze dried vials of antivenom. So, although there may be variability
between batches, the variability in dosing errors appears to be larger than the differences
between batches.
There are a number of limitations to the study including the fact that the sample collection
was not optimally designed and sample times (windows) were based on timing of clinical sam-
ples and other research assays required for the clinical trial. This is unlikely to have a major
Fig 2. Plots of antivenom concentration versus time for 1000 patients simulated from the final model individual predicted patient parameters for 10
vials of antivenom given over 20min, 1h and 2h, comparing the median concentrations for all three regimens (A), and the median and 10% and 90%
percentile concentrations for a 20 minute infusion (B), 1 hour infusion (C) and 2 hour infusion (D).
doi:10.1371/journal.pntd.0003873.g002
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influence on the analysis because a population approach will allow for both sparse and rich
sampling in patients. Another issue is that antivenom is not a pure substance and consists of
varying amounts of polyclonal antibodies to multiple toxins in the venom with varying affini-
ties. However, the assay uses a single detecting antibody (anti-horse antibody), so will detect all
antibodies against the snake toxins irrespective of their toxin target or affinity. Finally, the
assay will only detect antibodies that bind to the snake toxins. In most antivenoms, specific
antibodies to snake toxins make up only 10 to 20% of the total protein/immunoglobulin
Fig 3. Plots of antivenom concentration versus time for 1000 patients simulated from the final model individual predicted patient parameters for
patients given two doses of antivenom, the first given 10 vials over 1 hour and then repeated at 6 hours (A) and the second given 10 vials over 1
hour and then repeated at 12 hours (B), showingmedian, 10% and 90% percentile concentrations. The two regimens with repeat doses are compared
to a single dose in Panel C.
doi:10.1371/journal.pntd.0003873.g003
Pharmacokinetics of Indian Snake Antivenom
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content. This is unlikely to have affected the pharmacokinetic analysis because only immuno-
globulins binding to snake toxins are relevant to the analysis.
This population pharmacokinetic analysis demonstrates that Indian F(ab’)2 antivenom has
biexponential disposition kinetics and following an initial decline in antivenom concentrations
in the first 12 hours, low concentrations are present for days after administration. The study
demonstrates that the antivenom concentrations were not affected by the initial venom con-
centrations suggesting that sufficient antivenom in excess of the venom was being adminis-
tered. Understanding the pharmacokinetics of antivenom may assist in improving antivenom
dosing by matching antivenom pharmacokinetics to the neutralisation of venom (pharmaco-
dynamics), as well as clinical effects.
Supporting Information
S1 Fig. Plots of the relative fraction absorbed (F) versus batch number.
(TIF)
S2 Fig. Plots comparing Russell’s viper envenomed patients to hump-nosed viper enven-
omed patients for clearance (A), central volume (B), inter-compartmental clearance (C),
peripheral volume (D), half-life of distribution (E), half-life of elimination (F) and the rela-
tive fraction absorbed (G).
(TIF)
S3 Fig. Goodness-of-fit plots including a visual predictive check (VPC) showing the
observed data with the 10th, 50th, and 90th percentiles.
(TIF)
S4 Fig. A plot of observations versus individual predictions from the final model.
(TIF)
S5 Fig. Plots comparing patients receiving one versus two doses of antivenom and compar-
ing 3 different pre-antivenom venom concentrations (Low– 2 to 60ng/ml; Medium– 61 to
300ng/ml; High—>300ng/ml) for clearance (A), central volume (B), inter-compartmental
clearance (C), peripheral volume (D), half-life of distribution (E), half-life of elimination
(F) and the relative fraction absorbed (G).
(TIF)
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